Drugs / Lomvastomig
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03708328 | Oct 2018 → Jul 2024 | esophageal squamous cell carcinoma, metastatic melanoma, non-small cell lung carcinoma, small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04785820 | Jun 2021 → Jan 2025 | esophageal squamous cell carcinoma | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lomvastomig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04785820 ↗ |
| Known as | RO-7121661 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594602 ↗ |
| Action | Inhibit | “simultaneously blocks the immune checkpoint receptors programmed cell death protein 1 (PD-1) and T-cell immunoglobulin domain and mucin domain-3” PMID 42320980 ↗ Jun 20262“Hepatitis A virus cellular receptor 2 inhibitor” CHEMBL4594602 ↗ “Programmed cell death protein 1 inhibitor” CHEMBL4594602 ↗ |
| Modality | Monoclonal antibody | “an immunoglobulin G1-based Fc-silenced bispecific antibody” PMID 42320980 ↗ Jun 2026 |
| Route | Intravenous | “Lomvastomig will be administered intravenously (IV)” NCT03708328 ↗ |
| Target | HAVCR2 | “Hepatitis A virus cellular receptor 2 inhibitor” CHEMBL4594602 ↗ |
| Target | PDCD1 | “Programmed cell death protein 1 inhibitor” CHEMBL4594602 ↗ |